What is HC Wainwright’s Estimate for RCUS Q1 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($1.30) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $18.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.

Several other equities analysts also recently weighed in on the stock. Bank of America dropped their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday. Morgan Stanley cut their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday. Barclays increased their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Arcus Biosciences Stock Performance

Arcus Biosciences stock opened at $11.09 on Thursday. Arcus Biosciences has a fifty-two week low of $10.65 and a fifty-two week high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The stock’s fifty day moving average is $14.15 and its two-hundred day moving average is $15.60.

Hedge Funds Weigh In On Arcus Biosciences

A number of large investors have recently bought and sold shares of RCUS. Gilead Sciences Inc. purchased a new position in shares of Arcus Biosciences in the 4th quarter valued at $447,610,000. Boxer Capital Management LLC purchased a new position in Arcus Biosciences in the fourth quarter valued at about $23,857,000. Braidwell LP acquired a new position in shares of Arcus Biosciences during the fourth quarter worth about $11,943,000. Millennium Management LLC boosted its position in shares of Arcus Biosciences by 277.1% in the fourth quarter. Millennium Management LLC now owns 924,369 shares of the company’s stock worth $13,764,000 after buying an additional 679,267 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in shares of Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after buying an additional 610,219 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Activity

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.30% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.